| Income Statement | 2026-06-30 | |||
|---|---|---|---|---|
| Research and development | 9,180 | |||
| General and administrative expenses | 9,205 | |||
| Acquired in-process research and development | 0 | |||
| Total operating expenses | 18,385 | |||
| Loss from operations | -18,385 | |||
| Interest income, net | 2,258 | |||
| Other income (expense), net | 120 | |||
| Net loss | -16,007 | |||
| Basic EPS | -2.84 | |||
| Diluted EPS | -2.84 | |||
| Basic Average Shares | 5,643,222 | |||
| Diluted Average Shares | 5,643,222 | |||
Faeth Therapeutics, Inc. (FTH)
Faeth Therapeutics, Inc. (FTH)